Robison continues to serve as a Director.ĭr. In 2012 he co-founded a personalized medicine company called Tute Genomics Inc., which received venture capital financing from investors including Tencent and Intermountain Healthcare, before being acquired in 2016 by PerianDx Inc., where Dr. Robison has built and sold a number of purpose-driven companies including Anolinx Inc., a healthcare data analytics firm acquired by the Bennett Group in 2012. Robison supervises and trains ketamine-assisted psychotherapy practitioners across Utah, and to date has guided thousands of ketamine therapy journeys and, and hundreds of SpravatoTM dosing sessions.Īs a social entrepreneur, Dr. Food and Drug Administration (FDA) approval of SpravatoTM. Robison led the Utah site for the pivotal ketamine study for treatment-resistant depression by the Janssen, leading to the U.S. In 2011, he obtained his first grant to study ketamine and developed the ketamine depression protocols for the Intermountain Medical Center, Utah’s largest hospital. Robison was among the first clinicians to prescribe ketamine off-label for the treatment of depression in Utah. He also serves as the Medical Director for the Center for Change a highly respected eating disorder treatment center.ĭr.
#Novamind reviews trial
Robison serves as the Coordinating Investigator for the Multidisciplinary Association for Psychedelic Studies’ (MAPS) phase II clinical trial examining MDMA-assisted psychotherapy for the treatment of eating disorders. He has led over 100 clinical trials in neuropsychiatry and co-directed the University of Utah’s molecular genetics laboratory. Robison is a board-certified psychiatrist with fellowship training in neurodevelopmental genetics and clinical research. I’m enthusiastic about this role with Novamind, where together we will advance scientific research and create access to psychedelic-assisted psychotherapy for those who need it most.”ĭr. This partnership will allow us to develop and disseminate new ways of helping individuals and families struggling with mental health conditions, especially those for whom traditional treatments have been ineffective. Robison commented: “Novamind sits at the forefront of one of the most exciting opportunities to improve mental healthcare in our lifetimes. Robison is a thought leader in psychedelic medicine, widely recognized for his contributions as a clinician and researcher towards the use of psychedelic-assisted psychotherapy in psychiatry.ĭr. Robison co-founded Cedar Psychiatry LLC and Cedar Clinical Research LLC, organizations that were acquired by Novamind in July 2019. (“ Novamind”), a mental health and wellness company specialized in psychedelic-assisted psychotherapy, is pleased to announce that Reid Robison, MD, MBA, has been appointed Chief Medical Officer (“ CMO”) of Novamind.ĭr. TORONTO, ONTARIO / ACCESSWIRE / Aug/ Novamind Ventures Inc.
Any failure to comply with this restriction may constitute a violation of U.S.
Newswire Services or for dissemination in the United States.
0 kommentar(er)
